# OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.

> **NCT01842620** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01842620
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-13
- **Primary completion:** 2013-05-04
- **Final completion:** 2013-05-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01842620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01842620, "OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01842620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*